Bridge Pharmaceuticals, Inc. has acquired Gene Logic Labs (GLL), based in Gaithersburg, MD. Bridge will retain the services of all GLL employees, and the acquired unit’s name will become Bridge Global Development Services, Inc. (a subsidiary of Bridge Pharmaceuticals, Inc). Also, the two companies have entered into a preferred services agreement for preclinical drug development.

The acquisition of the Gene Logic Labs Gaithersburg facility enables Bridge to offer a complete IND suite of toxicology and pharmacology services on a global scale, according to the company. Combining the experience, technical staff and resources of U.S. operations with existing scientific staff in its new, purpose-built facility in Beijing, China, Bridge will provide the pharma industry with the high quality data required for worldwide regulatory submissions with "very significant cost savings."

“Many clients see the economies associated with performing preclinical work in Asia and want the assurances that work done there would be performed under the strict guidelines of U.S. level GLP regulatory requirements,” said Glenn Rice, Ph.D., chief executive officer and president of Bridge. “The GLL acquisition allows us to offer the unique benefits of our China facilities with the assurance of the regulatory compliance that clients require.”

News from our sister sites